Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

timeframes we anticipate or at all;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for each product;
  • our ability to increase manufacturing capacity for Cinryze and the timing and results thereof;
  • our ability to receive necessary regulatory approvals related to manufacturing capacity increases for Cinryze;
  • the size of the market, future growth potential and market share for Cinryze in the United States, Europe and other territories;
  • the availability of third party payer reimbursement for Cinryze patients;
  • fluctuations in wholesaler order patterns and inventory levels;
  • competition from the approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Cinryze, Vancocin, Buccolam and Plenadren;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin, Cinryze, Buccolam and Plenadren;
  • the impact of healthcare reform legislation;
  • actions by the FDA and EMA or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • the timing and results of anticipated events in our clinical development programs including studies with Cinryze subcutaneous formulation, Cinryze for antibody mediated rejection and delayed graft function, as well as VP20621 for recurrence of C. difficile; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring products in clinical development or marketed products.

  • There can be no assurance th
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... ... 2015 , ... The Kansas City Animal Health Investment Forum ... companies to hear from animal health companies with the newest technology. Companies presenting ... or distribution contracts. This meeting is one of the only investment forums ...
    (Date:8/27/2015)... 2015  Neogen Corporation (NASDAQ: NEOG ) announced ... United Kingdom -based Lab M Holdings, a ... diagnostic systems. Lab M was founded ... of microbial testing and diagnostic products for the global ... currently sells into more than 70 countries worldwide, and ...
    (Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
    (Date:8/27/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... June 30, 2015. Biorem,s complete second quarter financial statements and MD&A ... HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , Six -months endedJune ... 2015 , 2014 Revenue , 4,709 ... Gross profit , 1,656 , 56 , ...
    Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
    ... we just escaped January a notoriously depressing month ... and dank weather thats no surprise. In fact, ... week ago) was the most depressing day of the ... psychological burden because of the challenges they face, their ...
    ... for presentation times at the Midwest Venture Summit on May ... will be selecting only a handful of presenters out ... , ,Applicants will be reviewed by a panel of investors ... consider the products that each company is producing and developing, ...
    ... W.M. Keck Foundation of Los Angeles has given ... how stem-cell cultures remain able to develop any other type ... scientist James Thomson was the first to grow ... are given some impetus to form other kinds of cells ...
    Cached Biology Technology:Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4Follow the money 2Follow the money 3
    (Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
    (Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
    (Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
    Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
    ... Global Rainmakers, Inc., an intellectual property holding company ... has exited its "stealth" mode and is prepared to ... cutting-edge biometric security offerings. , During the past four ... dollars to develop and deploy a series of core--but ...
    ... Oct. 27, 2009 UT Southwestern Medical Center patient ... receive the newest generation of a mechanical device designed to ... awaits a heart transplant. Called a left-ventricular assist device ... pump blood throughout the body. For Mr. LeBlanc, it will ...
    ... discovered the pivotal role that volcanoes played in a ... ironically, these volcanoes first caused global warming -- by ... When they stopped erupting, Earth,s climate was thrown ... discovery underscores the importance of carbon in Earth,s climate ...
    Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Volcanoes played pivotal role in ancient ice age, mass extinction 2Volcanoes played pivotal role in ancient ice age, mass extinction 3
    4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
    RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
    RABBIT ANTI PARATHION...
    Recombinant Rhesus Monkey IFN-Alpha...
    Biology Products: